nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

26.05.2018 | Original Paper

Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort

verfasst von: Caroline Hurault-Delarue, Isabelle Lacroix, Anne Bénard-Laribière, Jean-Louis Montastruc, Antoine Pariente, Christine Damase-Michel

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Previous studies have suggested that exposure to some antidepressants (AD) during pregnancy could be associated with an increased risk of congenital malformations and neurodevelopment disorders for the child. We conducted a study to describe the use of AD during pregnancy in France.

Methods

We performed a drug utilisation study in EFEMERIS, a French cohort of pregnant women. At the time of the present study, 89,170 pregnant women, who were pregnant from 2005 to 2014 in Haute-Garonne were included. Prevalence and incidence of AD prescriptions during pregnancy, characteristics of AD users, and trends in AD use over the 10-year period were studied.

Results

During the 10-year study period, 1620 women registered in EFEMERIS (1.8%) received at least one prescription and dispensation for AD during pregnancy: 1363 during the first (1.5%), 591 during the second (0.7%), and 412 during the third (0.5%) trimester. A total of 2874 women (3.2%) got a prescription for an AD during the 3 months before and/or during pregnancy; 2187 of them (76.1%) stopped AD before pregnancy or during the first trimester. Selective serotonin reuptake inhibitors represented the most prescribed class during pregnancy (1.3%). A very slight decrease in the prevalence of AD prescriptions in pregnant women over time (1.7% in 2014 vs 2% in 2005) and some variations within classes were observed.

Conclusions

Nearly, 2% of women received antidepressant drugs during pregnancy. This assessment encourages following research on these drugs including the potential risk of neurodevelopmental disorders in children after an exposure to antidepressants during pregnancy.

Nur mit Berechtigung zugänglich

Bennett HA, Einarson A, Taddio A et al (2004) Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 103:698–709. https://doi.org/10.1097/01.AOG.0000116689.75396.5f CrossRefPubMed

Gavin NI, Gaynes BN, Lohr KN et al (2005) Perinatal depression: a systematic review of prevalence and incidence. Obstet Gynecol 106:1071–1083. https://doi.org/10.1097/01.AOG.0000183597.31630.db CrossRefPubMed

Jimenez-Solem E (2014) Exposure to antidepressants during pregnancy—prevalences and outcomes. Dan Med J 61:B4916PubMed

Bérard A, Chaabane S, Muanda FT et al (2016) Paroxetine use during pregnancy and the risk of cardiac defects. Br J Clin Pharmacol 82:566–567. https://doi.org/10.1111/bcp.12979 CrossRefPubMedPubMedCentral

Malm H, Artama M, Gissler M, Ritvanen A (2011) Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 118:111–120. https://doi.org/10.1097/AOG.0b013e318220edcc CrossRefPubMed

Huybrechts KF, Palmsten K, Avorn J et al (2014) Antidepressant use in pregnancy and the risk of cardiac defects. N Engl J Med 370:2397–2407. https://doi.org/10.1056/NEJMoa1312828 CrossRefPubMedPubMedCentral

Lassen D, Ennis ZN, Damkier P (2016) First-trimester pregnancy exposure to venlafaxine or duloxetine and risk of major congenital malformations: a systematic review. Basic Clin Pharmacol Toxicol 118:32–36. https://doi.org/10.1111/bcpt.12497 CrossRefPubMed

Huybrechts KF, Bateman BT, Palmsten K et al (2015) Antidepressant use late in pregnancy and risk of persistent pulmonary hypertension of the newborn. JAMA 313:2142–2151. https://doi.org/10.1001/jama.2015.5605 CrossRefPubMedPubMedCentral

Oberlander TF, Warburton W, Misri S et al (2006) Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 63:898–906. https://doi.org/10.1001/archpsyc.63.8.898 CrossRefPubMed

10.

Levinson-Castiel R, Merlob P, Linder N et al (2006) Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 160:173–176. https://doi.org/10.1001/archpedi.160.2.173 CrossRefPubMed

11.

Boukhris T, Sheehy O, Mottron L, Bérard A (2016) Antidepressant use during pregnancy and the risk of autism spectrum disorder in children. JAMA Pediatr 170:117–124. https://doi.org/10.1001/jamapediatrics.2015.3356 CrossRefPubMed

12.

Grzeskowiak LE, Morrison JL, Henriksen TB et al (2016) Prenatal antidepressant exposure and child behavioural outcomes at 7 years of age: a study within the Danish National Birth Cohort. BJOG Int J Obstet Gynaecol 123:1919–1928. https://doi.org/10.1111/1471-0528.13611 CrossRef

13.

Kaplan YC, Keskin-Arslan E, Acar S, Sozmen K (2016) Prenatal selective serotonin reuptake inhibitor use and the risk of autism spectrum disorder in children: a systematic review and meta-analysis. Reprod Toxicol 66:31–43. https://doi.org/10.1016/j.reprotox.2016.09.013 CrossRefPubMed

14.

Zoega H, Kieler H, Nørgaard M et al (2015) Use of SSRI and SNRI antidepressants during pregnancy: a population-based study from Denmark, Iceland, Norway and Sweden. PLoS One. https://doi.org/10.1371/journal.pone.0144474 CrossRefPubMedPubMedCentral

15.

Charlton R, Jordan S, Pierini A et al (2015) Selective serotonin reuptake inhibitor prescribing before, during and after pregnancy: a population-based study in six European regions. BJOG Int J Obstet Gynaecol 122:1010–1020. https://doi.org/10.1111/1471-0528.13143 CrossRef

16.

Hurault-Delarue C, Damase-Michel C, Finotto L et al (2016) Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database. Fundam Clin Pharmacol 30:476–482. https://doi.org/10.1111/fcp.12209 CrossRefPubMed

17.

Hurault-Delarue C, Chouquet C, Savy N et al (2016) How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women? Pharmacoepidemiol Drug Saf 25:770–777. https://doi.org/10.1002/pds.4000 CrossRefPubMed

18.

Lacroix I, Hurault C, Sarramon MF et al (2009) Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 65:839–846. https://doi.org/10.1007/s00228-009-0647-2 CrossRefPubMed

19.

WHOCC ATC classification. https://www.whocc.no/atc_ddd_index/?code=N06A&showdescription=no. Accessed 23 Mar 2017

20.

Bérard A, Sheehy O (2014) The Quebec pregnancy cohort—prevalence of medication use during gestation and pregnancy outcomes. PLoS One. https://doi.org/10.1371/journal.pone.0093870 CrossRefPubMedPubMedCentral

21.

Cooper WO, Willy ME, Pont SJ, Ray WA (2007) Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 196:544.e1–544.e5. https://doi.org/10.1016/j.ajog.2007.01.033

22.

Latendresse G, Elmore C, Deneris A (2017) Selective serotonin reuptake inhibitors as first-line antidepressant therapy for perinatal depression. J Midwifery Womens Health 62:317–328. https://doi.org/10.1111/jmwh.12607 CrossRefPubMed

23.

Fagot J-P, Cuerq A, Samson S, Fagot-Campagna A (2016) Cohort of one million patients initiating antidepressant treatment in France: 12-month follow-up. Int J Clin Pract 70:744–751. https://doi.org/10.1111/ijcp.12850 CrossRefPubMed

24.

Andrade SE, Raebel MA, Brown J et al (2008) Use of antidepressant medications during pregnancy: a multisite study. Am J Obstet Gynecol 198:194.e1–194.e5. https://doi.org/10.1016/j.ajog.2007.07.036

25.

ANSM (2006) Modification de la rubrique grossesse du Résumé des Caractéristiques du Produit (RCP) de Deroxat^® (chlorhydrate de paroxétine hémihydraté)—ANSM: Agence nationale de sécurité du médicament et des produits de santé. http://www.ansm.sante.fr/S-informer/Informations-de-securite-Lettres-aux-professionnels-de-sante/Modification-de-la-rubrique-grossesse-du-Resume-des-Caracteristiques-du-Produit-RCP-de-Deroxat-R-chlorhydrate-de-paroxetine-hemihydrate. Accessed 20 Dec 2016

26.

ANSM (2005) Paroxetine* et risque de malformation congénitale: points d’étape sur les résultats de l’évaluation européenne—ANSM : Agence nationale de sécurité du médicament et des produits de santé. http://ansm.sante.fr/S-informer/Presse-Communiques-Points-presse/Paroxetine-et-risque-de-malformation-congenitale-points-d-etape-sur-les-resultats-de-l-evaluation-europeenne. Accessed 20 Dec 2016

27.

FDA (2006) Postmarket drug safety information for patients and providers—public health advisory: treatment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124348.htm. Accessed 24 Mar 2017

28.

FDA (2005) Postmarket drug safety information for patients and providers—public health advisory: paroxetine. https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm051731.htm. Accessed 24 Mar 2017

29.

Howard LM, Molyneaux E, Dennis C-L et al (2014) Non-psychotic mental disorders in the perinatal period. Lancet 384:1775–1788. https://doi.org/10.1016/S0140-6736(14)61276-9 CrossRefPubMed

30.

Coll C, de VN, da Silveira, Bassani MF DG, et al (2017) Antenatal depressive symptoms among pregnant women: evidence from a Southern Brazilian population-based cohort study. J Affect Disord 209:140–146. https://doi.org/10.1016/j.jad.2016.11.031 CrossRefPubMedPubMedCentral

31.

Li Y, Long Z, Cao D, Cao F (2016) Maternal history of child maltreatment and maternal depression risk in the perinatal period: a longitudinal study. Child Abuse Negl 63:192–201. https://doi.org/10.1016/j.chiabu.2016.12.001 CrossRefPubMed

32.

Wong J, Motulsky A, Eguale T et al (2016) Treatment indications for antidepressants prescribed in primary care in Quebec, Canada, 2006–2015. JAMA 315:2230–2232. https://doi.org/10.1001/jama.2016.3445 CrossRefPubMed

33.

Cohen LS, Altshuler LL, Harlow BL et al (2006) Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 295:499–507. https://doi.org/10.1001/jama.295.5.499 CrossRefPubMed

34.

Yonkers KA, Gotman N, Smith MV et al (2011) Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiol Camb Mass 22:848–854. https://doi.org/10.1097/EDE.0b013e3182306847 CrossRef

35.

Hanley GE, Oberlander TF (2014) The effect of perinatal exposures on the infant: Antidepressants and depression. Best Pract Res Clin Obstet Gynaecol 28:37–48. https://doi.org/10.1016/j.bpobgyn.2013.09.001 CrossRefPubMed

36.

Wu J, Davis-Ajami ML (2014) Antidepressant treatment persistence in low-income, insured pregnant women. J Manag Care Spec Pharm 20:631–637. https://doi.org/10.18553/jmcp.2014.20.6.631 CrossRefPubMed

37.

Lupattelli A, Spigset O, Björnsdóttir I et al (2015) Patterns and factors associated with low adherence to psychotropic medications during pregnancy–a cross-sectional, multinational web-based study. Depress Anxiety 32:426–436. https://doi.org/10.1002/da.22352 CrossRefPubMed

38.

INSEE (2016) Les naissances en 2015. https://www.insee.fr/fr/statistiques/2106549?sommaire=2106619. Accessed 20 Dec 2016

Titel: Antidepressants during pregnancy: a French drug utilisation study in EFEMERIS cohort
verfasst von: Caroline Hurault-Delarue
Isabelle Lacroix
Anne Bénard-Laribière
Jean-Louis Montastruc
Antoine Pariente
Christine Damase-Michel
Publikationsdatum: 26.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 7/2019
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-018-0906-2

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Pharmacokinetic correlates of venlafaxine: associated adverse reactions

Association between serum lipid levels, osteoprotegerin and depressive symptomatology in psychotic disorders

Is (S)-norketamine an alternative antidepressant for esketamine?

Relationship between VEGF-related gene polymorphisms and brain morphology in treatment-naïve patients with first-episode major depressive disorder